[11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile after 24 months. (Articolo in rivista)

Type

• Articolo in rivista (Classe)
• Prodotto della ricerca (Classe)

Label

• [11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile after 24 months. (Articolo in rivista) (literal)

Anno

• 2010-01-01T00:00:00+01:00 (literal)

Alternative label

• Alongi F. 1-3, Schipani S.1, Gajate A.M. 4, Rosso A. 1, Cozzarini C. 1, Fiorino C. 5, Alongi P. 6, Picchio M. 4, Gianolli L. 4, Messa C. 7, Di Muzio N. 1 (2010)
  [11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile after 24 months.
  in Tumori (Testo stamp.))
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Alongi F. 1-3, Schipani S.1, Gajate A.M. 4, Rosso A. 1, Cozzarini C. 1, Fiorino C. 5, Alongi P. 6, Picchio M. 4, Gianolli L. 4, Messa C. 7, Di Muzio N. 1 (literal)

Pagina inizio

• 613 (literal)

Pagina fine

• 617 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

• 96 (literal)

Rivista

• Tumori (Rivista)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#note

• IF 2010: 1.014. (literal)

Note

• ISI Web of Science (WOS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• 1. Radiotherapy Department, San Raffaele Scientific Institute, Milano. 2. Istituto di Bioimmagini e Fisiologia Molecolare, Consiglio Nazionale delle Ricerche, Milano. 3. Intraoperative Radiotherapy and Image-Guided High-Focused Technologies, LATO, Hospital San Raffaele G. Giglio, Cefalù (PA). 4. Nuclear Medicine Department, and 5Medical Physics, Scientific Institute San Raffaele, Milano. 6. Medicine and Surgery School, University of Palermo, Palermo. 7. Milano-Bicocca University, Nuclear Medicine, H. San Gerardo, Monza. (literal)

Titolo

• [11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile after 24 months. (literal)

Abstract

• [11C]choline positron emission tomograhy can be useful to detect metastatic disease and to localize isolated lymph node relapse after primary treatment in case of prostate-specific antigen failure. In case of lymph node failure in prostate cancer patients, surgery or radiotherapy can be proposed with a curative intent. Some reports have suggested that radiotherapy could have a role in local control of oligometastatic lymph node disease. This is the first reported case of [11C]choline positron emission tomography-guided helical tomotherapy concomitant with estramustine for the treatment of pelvic-recurrent prostate cancer. At 24 months after the end of helical tomotherapy, prostate-specific antigen was undetectable and no late toxicities were recorded. A disease-free survival of 24 months, in the absence of any type of systemic therapy, is uncommon in metastatic prostate cancer. The therapeutic approach of the case report is discussed and a literature review on the issue is presented. (literal)

Prodotto di

• Tecniche terapeutiche innovative (ME.P06.005.001) (Modulo)
• Institute of molecular bioimaging and physiology (IBFM) (Istituto)

Autore CNR

• FILIPPO ALONGI (Unità di personale interno)

Insieme di parole chiave

• Keywords of "[11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile after 24 months." (Insieme di parole chiave)

Incoming links:

Autore CNR di

• FILIPPO ALONGI (Unità di personale interno)

Prodotto

• Institute of molecular bioimaging and physiology (IBFM) (Istituto)
• Tecniche terapeutiche innovative (ME.P06.005.001) (Modulo)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi

• Tumori (Rivista)

Insieme di parole chiave di

• Keywords of "[11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile after 24 months." (Insieme di parole chiave)